Announced
Completed
Financials
Sources
Tags
Acquisition
Single Bidder
Friendly
bioengineered research
Biotechnology
Private
United States
drug research
Majority
Completed
Private Equity
Domestic
Synopsis
Recursion, a digital biology company industrializing drug discovery, completed the acquisition of Vium, a creator of a fully digital end to end Digital Vivarium platform which is transforming in vivo research. Financial terms were not disclosed. “Bringing the fantastic team at Vium in-house will enable us to build on our core technology and vision, augmenting our huge in vitro datasets with large, complementary in vivo datasets, and advancing our mission to decode biology to radically improve patient lives,” Chris Gibson, Recursion Co-Founder and CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.